Cargando…

Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance

When locally advanced breast cancer is treated with neoadjuvant chemotherapy, the recurrence risk is significantly higher if no complete pathologic response is achieved. Identification of the underlying resistance mechanisms is essential to select treatments with maximal efficacy and minimal toxicit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoogstraat, Marlous, Lips, Esther H., Mayayo-Peralta, Isabel, Mulder, Lennart, Kristel, Petra, van der Heijden, Ingrid, Annunziato, Stefano, van Seijen, Maartje, Nederlof, Petra M., Sonke, Gabe S., Zwart, Wilbert, Wesseling, Jelle, Wessels, Lodewyk F. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076915/ https://www.ncbi.nlm.nih.gov/pubmed/35523804 http://dx.doi.org/10.1038/s41523-022-00428-8

Ejemplares similares

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response
por: Lips, Esther H., et al.
Publicado: (2015)

Tumour-educated platelets for breast cancer detection: biological and technical insights
por: Liefaard, Marte C., et al.
Publicado: (2023)

Correction To: Tumour-educated platelets for breast cancer detection: biological and technical insights
por: Liefaard, Marte C., et al.
Publicado: (2023)

Enrichment of high-grade tumors in breast cancer gene expression studies
por: van Seijen, M., et al.
Publicado: (2017)

RUBIC identifies driver genes by detecting recurrent DNA copy number breaks
por: van Dyk, Ewald, et al.
Publicado: (2016)

Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness
por: Lips, Esther H, et al.
Publicado: (2011)

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy
por: Vollebergh, Marieke A, et al.
Publicado: (2014)

Genome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors
por: Nevedomskaya, Ekaterina, et al.
Publicado: (2014)

Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2(+) breast cancer
por: Debets, Donna O., et al.
Publicado: (2023)

Ductal carcinoma in situ: to treat or not to treat, that is the question
por: van Seijen, Maartje, et al.
Publicado: (2019)

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ
por: Almekinders, Mathilde M. M., et al.
Publicado: (2021)

BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer
por: Lips, Esther H., et al.
Publicado: (2020)

The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review
por: Alaeikhanehshir, Sena, et al.
Publicado: (2020)

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments
por: Kester, Lennart, et al.
Publicado: (2022)

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
por: Groen, Emma J., et al.
Publicado: (2021)

Robust BRCA1‐like classification of copy number profiles of samples repeated across different datasets and platforms
por: Schouten, Philip C., et al.
Publicado: (2015)

Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast
por: van Seijen, Maartje, et al.
Publicado: (2021)

Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages
por: Kersten, Kelly, et al.
Publicado: (2017)

A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples
por: Zwart, Wilbert, et al.
Publicado: (2013)

Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo
por: Kim, Yongsoo, et al.
Publicado: (2019)

Variability in grading of ductal carcinoma in situ among an international group of pathologists
por: van Seijen, Maartje, et al.
Publicado: (2021)

SIRAC: Supervised Identification of Regions of Aberration in aCGH datasets
por: Lai, Carmen, et al.
Publicado: (2007)

A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression
por: Hutten, Stefan J., et al.
Publicado: (2023)

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation
por: Severson, Tesa M., et al.
Publicado: (2016)

CopywriteR: DNA copy number detection from off-target sequence data
por: Kuilman, Thomas, et al.
Publicado: (2015)

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth
por: Palit, Sander AL, et al.
Publicado: (2019)

High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial
por: Vliek, Sonja, et al.
Publicado: (2023)

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
por: Lips, E H, et al.
Publicado: (2013)

Androgen receptor DNA binding and chromatin accessibility profiling in prostate cancer
por: Nevedomskaya, Ekaterina, et al.
Publicado: (2015)

Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients
por: Sobral-Leite, Marcelo, et al.
Publicado: (2017)

PRI-CAT: a web-tool for the analysis, storage and visualization of plant ChIP-seq experiments
por: Muiño, Jose M., et al.
Publicado: (2011)

Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers
por: Holstege, Henne, et al.
Publicado: (2010)

Androgen receptor profiling predicts prostate cancer outcome
por: Stelloo, Suzan, et al.
Publicado: (2015)

Breast Cancer Subtype Specific Classifiers of Response to Neoadjuvant Chemotherapy Do Not Outperform Classifiers Trained on All Subtypes
por: de Ronde, Jorma J., et al.
Publicado: (2014)

Array-CGH and breast cancer
por: van Beers, Erik H, et al.
Publicado: (2006)

Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer
por: Lips, Esther H., et al.
Publicado: (2022)

Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis
por: van Amerongen, Rosa A, et al.
Publicado: (2016)

PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning
por: Aswolinskiy, Witali, et al.
Publicado: (2023)

Androgen and glucocorticoid receptor direct distinct transcriptional programs by receptor-specific and shared DNA binding sites
por: Kulik, Marina, et al.
Publicado: (2021)

Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study
por: Groen, Emma J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ffi493mhtrqf1nah2319gqnmc2